Healthcare · Medical - Devices
Price
$5.96
Market Cap
$13.4M
Employees
64
Beta
1.49
Avg Volume
3,003,547
CEO
Eyal Shamir
Business Description
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Business History
Price Overview
Last updated: Jun 27, 2026 8:01am (just now)$5.96
-1.06 (-15.10%)
Day Range
$5.60 – $6.55
52-Week Range
$2.12 – $42.00
50-Day MA
$6.79
200-Day MA
$17.26
Volume
769,119.00
Analyst Price Targets
Low
$1.00
Consensus
$1.00
High
$1.00
(5 analysts)
Share Structure
Outstanding
2,252,053.00
Float
1,520,609.00
Free Float
67.5%
Normal free float
— 67.5% of shares trade freely, ~32.5% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Small absolute float (1.5M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.84
Stock Price: $5.96
EPS (Diluted): -7.10
EPS (Diluted): -7.10
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
4.28
Stock Price: $5.96
Total Equity: $9.05M
Shares: 2,119,308
Total Equity: $9.05M
Shares: 2,119,308
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.35
Market Cap: $13.42M
Total Debt: $0.00
Cash: $8.90M
EBITDA: -$14.80M
Total Debt: $0.00
Cash: $8.90M
EBITDA: -$14.80M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$30.1M
Market Cap: $13.42M
Total Debt: $0.00
Cash: $8.90M
Total Debt: $0.00
Cash: $8.90M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
11.48
Stock Price: $5.96
Revenue: $3.38M
Shares: 2,119,308
Revenue: $3.38M
Shares: 2,119,308
EV/Sales (Total value vs revenue — works when P/E can't)
API8.91
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
36.3%
Gross Profit: $1.23M
Revenue: $3.38M
Revenue: $3.38M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-446.7%
Operating Income: -$15.09M
Revenue: $3.38M
Revenue: $3.38M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-445.6%
Net Income: -$15.06M
Revenue: $3.38M
Revenue: $3.38M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-211.7%
Net Income: -$15.06M
Total Equity: $9.05M
Total Equity: $9.05M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-344.8%
Operating Income: -$15.09M
Tax Rate: 0.0%
Equity: $9.05M
Total Debt: $0.00
Cash: $8.90M
Tax Rate: 0.0%
Equity: $9.05M
Total Debt: $0.00
Cash: $8.90M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.61
Current Assets: $12.61M
Current Liabilities: $4.82M
Current Liabilities: $4.82M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $9.05M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $9.05M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$1.59
Revenue: $3.38M
Shares: 2,119,308
Shares: 2,119,308
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$4.27
Total Equity: $9.05M
Shares: 2,119,308
Shares: 2,119,308
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-6.89
Operating CF: -$14.57M
CapEx: -$36,000
Shares: 2,119,308
CapEx: -$36,000
Shares: 2,119,308
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $5.96
Stock Price: $5.96
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$15.06M
Net Income: -$15.06M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ICCM against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 9:19am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.1M | $3.1M | $3.2M | $3.3M | $3.4M |
| Cost of Revenue | $1.9M | $1.6M | $1.9M | $1.8M | $2.2M |
| Gross Profit | $2.2M | $1.4M | $1.3M | $1.5M | $1.2M |
| Operating Expenses | $11.9M | $18.2M | $16.9M | $17.1M | $16.3M |
| Operating Income | -$9.7M | -$16.7M | -$15.6M | -$15.7M | -$15.1M |
| Net Income | -$10.1M | -$17.2M | -$14.7M | -$15.3M | -$15.1M |
| EBITDA | -$9.6M | -$16.5M | -$15.3M | -$15.4M | -$14.8M |
| EPS | $-10.50 | $-14.10 | $-9.60 | $-9.00 | $-7.10 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 9:19am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $25.6M | $23.7M | $10.5M | $7.6M | $8.9M |
| Total Current Assets | $30.3M | $28.1M | $14.2M | $10.8M | $12.6M |
| Total Assets | $32.3M | $30.2M | $16.4M | $12.6M | $13.9M |
| Current Liabilities | $4.0M | $4.3M | $3.9M | $5.5M | $4.8M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.3M | $4.8M | $4.2M | $5.7M | $4.8M |
| Total Equity | $27.0M | $25.4M | $12.2M | $6.9M | $9.1M |
| Retained Earnings | -$58.4M | -$75.4M | -$90.1M | -$105.4M | -$120.4M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 9:19am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$12.6M | -$14.3M | -$12.5M | -$12.6M | -$14.6M |
| Capital Expenditure | $-533,000 | $-891,000 | $-480,000 | $-71,000 | $-36,000 |
| Free Cash Flow | -$13.1M | -$15.2M | -$13.0M | -$12.6M | -$14.6M |
| Acquisitions (net) | -$4.5M | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $22.1M | -$2.0M | -$13.1M | -$3.0M | $1.3M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:01am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$12.5M $10.5M – $15.0M
|
$26.1M $21.9M – $31.2M
|
$42.2M $35.3M – $50.4M
|
$59.9M $50.2M – $71.5M
|
| EBITDA |
-$12.5M -$15.0M – -$10.5M
|
-$26.1M -$31.2M – -$21.9M
|
-$42.2M -$50.4M – -$35.3M
|
-$59.9M -$71.5M – -$50.2M
|
| Net Income |
-$8.4M -$10.3M – -$6.5M
|
-$3.6M -$4.5M – -$2.7M
|
$296,703 $233,992 – $371,366
|
$4.0M $3.2M – $5.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 9:19am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -25.4% | +4.7% | +1.9% | +2.7% |
| Gross Profit Growth | -34.2% | -10.0% | +11.6% | -15.5% |
| Operating Income Growth | -72.1% | +6.9% | -0.8% | +3.8% |
| Net Income Growth | -71.0% | +14.9% | -4.5% | +1.7% |
| EBITDA Growth | -71.8% | +7.5% | -0.7% | +3.7% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-12 | Muchnik Naum | 0.00 | $0.00 | $0 | |
| 2026-05-17 | Tsimerman Ronen | 0.00 | $0.00 | $0 | |
| 2026-05-17 | Peleg Meir | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Malca Yonatan | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Huang Yang | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Huang Yang | 25,000.00 | $1.70 | $42,500 | |
| 2026-03-18 | Huang Yang | 80,668.00 | $3.64 | $293,632 | |
| 2026-03-18 | Huang Yang | 40,705.00 | $1.51 | $61,465 | |
| 2026-03-18 | Chan Vincent Chun Hung | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Tel-Tzure Tlalit Bussi | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Tel-Tzure Tlalit Bussi | 50,000.00 | $2.27 | $113,500 | |
| 2026-03-18 | Tel-Tzure Tlalit Bussi | 29,594.00 | $1.56 | $46,167 | |
| 2026-03-18 | Tel-Tzure Tlalit Bussi | 1,370.00 | $5.78 | $7,919 | |
| 2026-03-18 | Tel-Tzure Tlalit Bussi | 80,668.00 | $3.64 | $293,632 | |
| 2026-03-18 | Tel-Tzure Tlalit Bussi | 3,743.00 | $2.84 | $10,630 | |
| 2026-03-18 | Tel-Tzure Tlalit Bussi | 40,705.00 | $1.51 | $61,465 | |
| 2026-03-18 | Tel-Tzure Tlalit Bussi | 81,818.00 | $0.92 | $75,273 | |
| 2026-03-18 | Levav Shay | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Levav Shay | 50,000.00 | $1.56 | $78,000 | |
| 2026-03-18 | Levav Shay | 385.00 | $5.78 | $2,225 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ICCM — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ICCM.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30